|

QTORIN 3.9% Rapamycin Anhydrous Gel Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • Palvella Therapeutics, Inc.1

Indications

  • Microcystic Lymphatic Malformation1
  • Cancer1

Irvine, California1 trial

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

Children's Hospital of Orange County

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.